GlaxoSmithKline (GSK) Rating Reiterated by Liberum Capital

GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reiterated by research analysts at Liberum Capital in a report issued on Thursday, March 22nd. They presently have a GBX 1,630 ($23.34) target price on the stock. Liberum Capital’s price target indicates a potential upside of 15.39% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Goldman Sachs set a GBX 1,775 ($25.42) price target on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Friday, December 1st. Berenberg Bank restated a “buy” rating and issued a GBX 1,760 ($25.20) price objective on shares of GlaxoSmithKline in a research note on Wednesday, December 13th. UBS set a GBX 1,550 ($22.19) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Wednesday, December 13th. HSBC restated a “buy” rating and issued a GBX 1,925 ($27.56) price objective on shares of GlaxoSmithKline in a research note on Wednesday, November 22nd. Finally, Jefferies Group restated a “buy” rating and issued a GBX 1,500 ($21.48) price objective on shares of GlaxoSmithKline in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have issued a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of GBX 1,554.32 ($22.26).

How to Become a New Pot Stock Millionaire

Shares of GlaxoSmithKline stock traded up GBX 4 ($0.06) during trading on Thursday, hitting GBX 1,412.60 ($20.23). 6,363,407 shares of the stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($17.69) and a 12-month high of GBX 1,724.50 ($24.69).

In other GlaxoSmithKline news, insider Victoria Whyte sold 4,544 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,307 ($18.71), for a total value of £59,390.08 ($85,037.34). Also, insider Patrick Vallance sold 14,022 shares of the company’s stock in a transaction dated Monday, February 19th. The shares were sold at an average price of GBX 1,318 ($18.87), for a total transaction of £184,809.96 ($264,619.07). In the last three months, insiders have purchased 589 shares of company stock worth $754,828 and have sold 23,765 shares worth $31,152,709.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline (GSK) Rating Reiterated by Liberum Capital” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://weekherald.com/2018/04/17/glaxosmithklines-gsk-buy-rating-reaffirmed-at-liberum-capital.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply